NEALS has built far more than a research network—it has created a collaborative learning ecosystem that brings together clinicians, researchers, people living with ALS, and advocates to drive excellence in ALS clinical trials.

From the outset, NEALS functioned as a clinical trial network, advancing innovation in how ALS trials are designed, conducted, and evaluated. The network has supported a broad range of study designs – including early-phase studies; Phase 1, 2, and 3 trials; adaptive and platform trials; and novel approaches such as ALS MyMatch – expanding access while improving efficiency and scientific rigor.

NEALS investigators have played a central role in developing and validating trial designs and outcome measures that now define high-quality ALS research. At the same time, NEALS invested heavily in trial conduct and site readiness, training investigators, coordinators, and evaluators to ensure consistency, accuracy, and excellence across the network.

This integrated approach – innovative design paired with rigorous execution – has helped make ALS an increasingly attractive field for pharmaceutical and biotechnology partners. As the science of ALS has advanced and more therapeutic candidates have entered development, NEALS has ensured that the infrastructure exists to test them efficiently and thoughtfully, with the patient voice embedded throughout the process.

NEALS has also cultivated expertise by attracting and training leading biostatisticians and trial designers, strengthening collaboration between quantitative experts and clinical investigators. Through workshops, mentorship, and formal training programs, NEALS fosters continuous learning and shared problem-solving across the ALS research community.